Director/PDMR Shareholding

RNS Number : 7244E
Proteome Sciences PLC
10 May 2017
 

Proteome Sciences plc

("Proteome Sciences" or the "Company")

Director/PDMR Shareholding

The Company has received notification from Vulpes Life Sciences Fund ("Vulpes") that it has made the following purchases of ordinary shares of 1p each in the capital of the Company ("Ordinary Shares") (the "Purchases"):

Date

Ordinary Shares purchased

Price paid per Ordinary Share (p)

5th May 2017

1,117

4.8

8th May 2017

100,000

5.0

9th May 2017

100,000

5.0

Following the Purchases Vulpes has a total direct and indirect interest in 54,346,401 equivalent to 18.44% of Proteome Sciences' total issued share capital.

The Company would also like to announce that by virtue of Martin Diggle being a Director of both Vulpes and the Company, he now has an interest in 54,346,401 Ordinary Shares of the Company representing 18.44% of the issued share capital of the Company.

 

 1.               

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Vulpes Life Sciences Fund

2.               

Reason for the Notification

a)

Position/status

PCA of Martin Diggle (NED)

b)

Initial notification/Amendment

Initial notification

3.    

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Proteome Sciences plc

b)

LEI

n/a

4.    

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the Financial instrument, type of instrument

Ordinary Shares of 1p each

Identification code

GB0003104196

b)

Nature of the transaction

Purchase

c)

Price(s) and volume(s)

1,117 Ordinary Shares at 4.8p per Ordinary Shares

100,000 Ordinary Shares of 5.0p per Ordinary Shares 100,000 Ordinary Shares at 5.0p per Ordinary Shares

d)

Aggregated information:

·      Aggregated volume

·      Price

 

201,117 Ordinary Shares of 1p each purchased at a volume weighted average price of 5.00p per Ordinary Share

e)

Date of the transaction

5 May 2017 (First Purchase), 8 May 2017 (Second Purchase), 9 May 2017 (Third Purchase)

f)

Place of the transaction

London Stock Exchange, AIM Market (XLON)

 

 

For further information:

 Proteome Sciences plc

Dr Jeremy Haigh, Chief Executive Officer                          Tel: +44 (0)1932 865065

Dr Ian Pike, Chief Scientific Officer


Geoff Ellis, Finance Director

 

finnCap Limited (Nominated Adviser/Broker)

 

        

Geoff Nash/James Thompson

Tel: +44 (0)20 7220 0500

Tony Quirke (broking)

 IFC Advisory (Financial PR and IR)

Tim Metcalfe/Graham Herring/Miles Nolan

            Tel: +44 (0)20 3053 8671


               

 Notes for editors:

 Proteome Sciences is a leader in applied proteomics offering high sensitivity, proprietary technologies and workflows for mapping cell signalling pathways (SysQuant®, TMTcalibrator) and for the discovery, validation and assay development of protein biomarkers. The company has its headquarters in Cobham, UK, with laboratory facilities in Frankfurt, Germany from where the PS Biomarker Services division provides outsourced proteomics services and proprietary biomarker assays to biopharmaceutical and diagnostics companies and to academia.

 Proteome Sciences has patented a number of novel protein biomarkers for diagnostic and treatment applications in important areas of human therapeutics such as cancer, stroke and Alzheimer's disease, and these are available for license.

 

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DSHSFISUSFWSESI
UK 100

Latest directors dealings